Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expr…

Initiation of trial marks milestone for Crinetics’ novel nonpeptide drug conjugate platformSAN DIEGO, Dec. 03, 2025 (GLOBE ...